Often referred to as the “father of agricultural biotechnology”, Dr. Jerry Caulder has an unparalleled record of success in the life sciences industry. Dr. Caulder’s career began at Monsanto. During his fifteen years with the company, he held numerous management positions. Dr. Caulder was responsible for overseeing Monsanto’s early venture investments and also the launch of new agricultural products globally.
In 1984 Dr. Caulder moved to San Diego, California, and became The Chairman and CEO of Mycogen, Inc., a start-up plant sciences company. Under Dr. Caulder’s direction, Mycogen, Inc. had a successful IPO and was ultimately acquired by Dow Agro Sciences in 1998. At the time of acquisition, Mycogen’s market capitalization exceeded US$1.2 billion.
Since the acquisition success of Mycogen, Dr. Jerry Caulder has held leadership positions in a number of successful and highly profiled life science companies including: Myelos Pharmaceuticals, a therapeutic drug discovery company focusing on the treatment of diabetic neuropathy, and Advanced Stent Technologies, Inc., which focused on the development of a dedicated coronary bifurcation stent.
Dr. Caulder’s most recent success was as the Chairman of Athenix, Inc., a venture backed plant sciences company located in Research Triangle Park, NC. Athenix’s acquisition by Bayer Crop Science in November 2009, for $400 million delivered a substantial return on investment to its shareholders.
Dr. Caulder has been involved in the formation of many local, state, and national biotech industry groups and initiatives; he was also the Chairman of what is now “BIO” (the major Biotechnology trade association). Dr. Caulder is internationally recognized and a frequent speaker at industry forums.